Taiwan Liposome
TLC BioSciences is a pioneering biotechnology company dedicated to developing innovative nanomedicines and lipid-based drug delivery technologies. With a rich history dating back to 1997, the company focuses on creating treatments that address unmet medical needs, particularly in orthopedics, pain management, and infectious diseases. Leveraging proprietary platforms like LipAD®, BioSeizer®, NanoX®, and Genosphere™, TLC has successfully developed and commercialized several liposomal drugs and gene therapies. The company emphasizes safety, efficacy, and patient-centric solutions, with a global presence and a commitment to advancing healthcare through cutting-edge research and strategic partnerships.
Industries
Nr. of Employees
medium (51-250)
Taiwan Liposome
2F, 3 Park Street, Nangang District, Taipei City, Taiwan
Patents
Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof
US-12285524-B2
View DetailsSustained-release pharmaceutical compositions comprising an immunomodulating agent and uses thereof
US-12274785-B2
View DetailsSustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof
US-12268781-B2
View DetailsPharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
US-12208104-B2
View DetailsSustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
US-12005142-B2
View Details
Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof
US-12285524-B2
View DetailsSustained-release pharmaceutical compositions comprising an immunomodulating agent and uses thereof
US-12274785-B2
View DetailsSustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof
US-12268781-B2
View DetailsPharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
US-12208104-B2
View DetailsSustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
US-12005142-B2
View DetailsProducts
Liposomal amphotericin B injectable (complex generic, marketed)
A liposomal amphotericin B intravenous product developed as a complex generic alternative for treatment of systemic fungal infections with reduced toxicity and improved tolerability.
Extended‑release dexamethasone intra‑articular injectable (OA)
A multi‑layer lipid injectable formulation of dexamethasone sodium phosphate designed for local sustained release in joints to provide prolonged analgesic effect for osteoarthritis.
PEGylated liposomal vinorelbine formulation (oncology)
A PEGylated liposomal formulation of vinorelbine developed for pediatric and rare soft tissue sarcomas to reduce systemic toxicity and increase tumor-directed exposure.
LNP-based gene therapy candidate for articular tissue regeneration (preclinical)
A lipid nanoparticle formulation for delivery of RNA intended to prevent articular tissue degeneration and stimulate regeneration as a disease-modifying osteoarthritis therapeutic.
Preclinical small‑molecule chondroprotection candidate
A lipid-formulated small molecule designed to protect cartilage and stimulate chondrogenesis as a potential disease-modifying osteoarthritis therapy.
Extended‑release dexamethasone intraocular injectable (ophthalmology, pipeline)
An extended‑release injectable formulation of dexamethasone sodium phosphate for ophthalmic indications such as macular edema, using multi-layer lipid encapsulation to sustain therapeutic levels.
Liposomal amphotericin B injectable (complex generic, marketed)
A liposomal amphotericin B intravenous product developed as a complex generic alternative for treatment of systemic fungal infections with reduced toxicity and improved tolerability.
Extended‑release dexamethasone intra‑articular injectable (OA)
A multi‑layer lipid injectable formulation of dexamethasone sodium phosphate designed for local sustained release in joints to provide prolonged analgesic effect for osteoarthritis.
PEGylated liposomal vinorelbine formulation (oncology)
A PEGylated liposomal formulation of vinorelbine developed for pediatric and rare soft tissue sarcomas to reduce systemic toxicity and increase tumor-directed exposure.
LNP-based gene therapy candidate for articular tissue regeneration (preclinical)
A lipid nanoparticle formulation for delivery of RNA intended to prevent articular tissue degeneration and stimulate regeneration as a disease-modifying osteoarthritis therapeutic.
Preclinical small‑molecule chondroprotection candidate
A lipid-formulated small molecule designed to protect cartilage and stimulate chondrogenesis as a potential disease-modifying osteoarthritis therapy.
Extended‑release dexamethasone intraocular injectable (ophthalmology, pipeline)
An extended‑release injectable formulation of dexamethasone sodium phosphate for ophthalmic indications such as macular edema, using multi-layer lipid encapsulation to sustain therapeutic levels.
Services
Discovery, lipid-based formulation development, preclinical testing, and clinical trial execution for nanomedicine candidates from preclinical stages through late-phase trials.
Process development, analytical CMC planning, and transfer to contract manufacturers with oversight of GMP batch manufacturing for clinical supply and commercial registration.
Advisory services for regulatory submissions, securing orphan/rare designations, and managing national regulatory reviews toward approval.
In vivo efficacy testing, biodistribution and pharmacokinetic studies, and molecular imaging to support IND-enabling packages and clinical strategies.
Partner selection, licensing and distribution planning to enable regional market entry and post-approval commercialization.
Discovery, lipid-based formulation development, preclinical testing, and clinical trial execution for nanomedicine candidates from preclinical stages through late-phase trials.
Process development, analytical CMC planning, and transfer to contract manufacturers with oversight of GMP batch manufacturing for clinical supply and commercial registration.
Advisory services for regulatory submissions, securing orphan/rare designations, and managing national regulatory reviews toward approval.
In vivo efficacy testing, biodistribution and pharmacokinetic studies, and molecular imaging to support IND-enabling packages and clinical strategies.
Partner selection, licensing and distribution planning to enable regional market entry and post-approval commercialization.
Expertise Areas
- Liposomal drug delivery
- Lipid nanoparticle (LNP) RNA and gene delivery
- Non-viral lipid-based gene therapy delivery
- Orthopedics and pain‑management nanomedicines
Key Technologies
- Liposomal formulation platforms
- PEGylated lipid carriers
- Lipid nanoparticles (LNP) for nucleic-acid delivery
- Condensed lipid–nucleic acid complexes (non-viral gene delivery)
News & Updates
TLC's generic liposomal amphotericin B, Ampholipad, received approval from China's NMPA, marking a milestone in its global expansion and commitment to addressing unmet medical needs.
TLC599 demonstrated reduction in pain and improved function for osteoarthritis knee pain, with effects lasting up to 24 weeks and benefits extended with repeat injections.
The Phase 3 study showed that TLC599 provides durable pain relief for osteoarthritis of the knee, with benefits sustained up to 52 weeks, and was well tolerated.
TLC's generic liposomal amphotericin B, Ampholipad, received approval from China's NMPA, marking a milestone in its global expansion and commitment to addressing unmet medical needs.
TLC599 demonstrated reduction in pain and improved function for osteoarthritis knee pain, with effects lasting up to 24 weeks and benefits extended with repeat injections.
The Phase 3 study showed that TLC599 provides durable pain relief for osteoarthritis of the knee, with benefits sustained up to 52 weeks, and was well tolerated.